FGF21 and obesity disorder: FGF21 was first described in 2000 by Nishimura et al. [9] and is considered an attractive therapeutic target to treat obesity and obesity-related metabolic disorders due to its beneficial effects in lipid and carbohydrate metabolism [10,11,12,13].